US FDA gives CordenPharma Latina's Italian plant the all clear

By Gareth Macdonald

- Last updated on GMT

Google Maps
Google Maps

Related tags Pharmacology Pharmaceutical drug

CordenPharma Latina has resolved the problems that earned its API and injectable drug facility in Sermoneta, Italy a warning letter from the US FDA last year.

The US regulator gave the plant a clean bill of health in a closeout letter​ this month, explaining that: “Based on our evaluation, it appears that you have addressed the violations and or deviations.”

The Sermoneta facility – which was previously owned by Bristol Myers - makes oral and sterile liquid dosage forms antibiotics, including cephalosporin and penicillins. It was also cleared to manufacture freeze-dried cancer drugs for clinical trials in July 2015.

CordenPharma – which is owned by Germany-based International Chemical Investors Group (ICIG) – said addressing the issues – which were detailed in a warning letter in May​ last year – had involved a “holistic and systematic approach​.”

The firm declined to comment further when contacted by in-Pharmatechnologist.com.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars